Abstract
This article describes a rare clinical case of prostate cancer with a high baseline PSA level of 1407 hg/ml. In the course of diagnosis, hormonal and surgical treatment there was a successive dynamics of PSA decline: 07.08.2015–1407 ng/ ml, 14.09.2015–43,61ng/ml; 17.11.2015–0,326 ng/ml; 13.02.2016 (end of hormone therapy) — 0,084 ng/ml. After the operation of radical prostatectomy with enlarged lymphadenectomy, on 20.04.2016 (with prolonged hormone therapy up to 9 monthes) gradual decrease of PSA level continued: 05.05.2016–0,008 ng/ml; 17.06.2016–0,008 ng/ml; 08.09.2016–0,039 ng/ml; 30.11.2016–0,002 ng/ml; 07.09.2017 (total PSA) — 0,008 ng/ml. In parallel, there was a consistent improvement in the clinical picture, up to the MRI data of 19.10.2017, when there were no significant neoplastic changes at the level of the study (in the projection of the prostatic bed).
Highlights
All authors report no conflict of interest
Параллельно было выявлено последовательное улучшение клинической картины, вплоть до данных магнитно-резонансная томография (МРТ) от 19.10.2017 г., когда не было найдено достоверных неопластических изменений на уровне исследования (в проекции ложа предстательной железы)
Summary
Параллельно констатировалось последовательное улучшение клинической картины, вплоть до данных МРТ от 19.10.2017 г., когда не было выявлено достоверных неопластических изменений на уровне исследования (в проекции ложа предстательной железы). Ключевые слова: рак предстательной железы, динамика уровня ПСА, комбинированное лечение (гормональное и хирургическое) PROSTATE CANCER WITH A HIGH BASELINE PSA LEVEL AFTER COMBINED TREATMENT
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
